Skip to main content
. 2023 Mar 18;14(3):202. doi: 10.1038/s41419-023-05724-0

Fig. 7. DYRK2 regulates chemotherapy resistance via FBXW7.

Fig. 7

A Survival clonogenic assay of HEK-293T cells in the conditions indicated and treated with DOX (2 μM) for 24 h prior to cell plating in diluted conditions. Quantification of the data is shown in the bar graph (mean ± SD, n = 3; *P < 0.05, **P < 0.01). Expression of the indicated proteins was assessed by WB in parallel samples. B Jurkat cells (FBXW7 R505C) or C MOLT-4 cells (FBXW7 WT) were transfected with Flag-DYRK2, and treated with OTX-015 for 48 h at the concentrations indicated. Viability was analyzed by XTT assay. D HCT116 cells were transfected with the indicated siRNAs or plasmids, and the endogenous levels of the specified proteins were analyzed by WB. E Cell viability of HCT116 cells transfected with the indicated siRNAs or plasmids was evaluated by MTT assay in the presence or absence of Paclitaxel (100 nM) treatment for 72 h and presented as relative to the untreated control (mean ± SD, n = 4; *P < 0.05, **P < 0.01, ***P < 0.001). Note: a representative experiment is shown in each panel out of 3–4 performed.